AMG-131 | 315223-08-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: AMG-131
• 英文别名: 2-chloro-N-(3,5-dichloro-4-quinolin-3-ylsulfanylphenyl)-4-(trifluoromethyl)benzenesulfonamide
• CAS: 315223-08-6
• 化学式: C₂₂H₁₂Cl₃F₃N₂O₂S₂
• 分子量: 563.836
• InChiKey: RZDCVXDYKNXBCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.6
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  92.7
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• QUINOLINYL AND BENZOTHIAZOLYL MODULATORS
  申请人：McGee Lawrence R.

  公开号：US20090221635A1

  公开（公告）日：2009-09-03

  Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPARγ. In particular, the compounds of the invention modulate the function of PPARγ. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.

  本发明提供了一些化合物、组合物和方法，它们对于治疗或预防由PPARγ介导的疾病或疾病非常有用。特别地，本发明的化合物调节PPARγ的功能。该方法特别适用于治疗和/或预防糖尿病、肥胖症、高胆固醇血症、类风湿性关节炎和动脉粥样硬化。
• PHARMACEUTICAL COMPOSITION CONTAINING PPAR GAMMA AGONIST
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1905450A1

  公开（公告）日：2008-04-02

  [OBJECT] To provide a highly safe method for treating diabetes that demonstrates superior effects and is capable of inhibiting adverse side effects. [MEANS FOR SOLUTION] A pharmaceutical containing a PPARγ agonist, and a pharmaceutical composition in combination with a biguanide agent and a PPARγ agonist.

  目的 提供一种高度安全的治疗糖尿病的方法，它能显示出卓越的效果，并能抑制不良副作用。 [解决方法］ 一种含有 PPARγ 激动剂的药物，以及一种与双胍类药物和 PPARγ 激动剂联合使用的药物组合物。
• MEDICAL AGENT CONTAINING INSULIN RESISTANCE IMPROVING AGENT
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1935432A1

  公开（公告）日：2008-06-25

  To provide a method for treating diabetes which has an excellent blood glucose lowering action and causes minimal adverse drug reactions, there is provided a medicine comprising a DPP-IV inhibitor in combination with an insulin sensitizer.

  为了提供一种降血糖效果极佳且药物不良反应极小的糖尿病治疗方法，本发明提供了一种由 DPP-IV 抑制剂与胰岛素增敏剂组合而成的药物。
• Pharmaceutical agent comprising insulin resistance improving agent
  申请人：Kanda Shoichi

  公开号：US20090124626A1

  公开（公告）日：2009-05-14

  To provide a method for treating diabetes which has an excellent hypoglycemic action and causes minimal adverse drug reactions, there is provided a medicine comprising a DPP-IV inhibitor and an insulin sensitizer in combination.
• Pharmaceutical Composition Containing PPARgamma Agonist
  申请人：Okuno Akira

  公开号：US20090137626A1

  公开（公告）日：2009-05-28

  [Object] To provide a highly safe method for treating diabetes that demonstrates superior effects and is capable of inhibiting adverse side effects. [Means for Solution] A pharmaceutical containing a PPARγ agonist, and a pharmaceutical composition in combination with a biguanide agent and a PPARγ agonist.